Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 23;4(2):54-8.
doi: 10.1016/j.jbo.2015.06.001. eCollection 2015 Jun.

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

Carmel Jacobs  1 , Eitan Amir  2 , Alexander Paterson  3 , Xiaofu Zhu  1 , Mark Clemons  1
Affiliations
Review

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

Carmel Jacobs et al. J Bone Oncol. .

Abstract

The 9th Bone and the Oncologist New Updates conference was held in Ottawa, Canada during 2014. This annual meeting focuses on innovative research into the mechanisms and consequences of treatment-induced and metastatic bone disease. Given the recent presentation of the Oxford overview's "Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomized trials" at the San Antonio Breast Cancer Symposium, a debate as to the pro's and con's of adjuvant bisphosphonate use in early stage breast cancer was undertaken. As bisphosphonate treatment in post-menopausal women appeared to demonstrate a similar magnitude of benefit to that of other commonly used adjuvant strategies the debate assessed whether or not there was sufficient data to incorporate adjuvant bisphosphonates into standard practice and if so, in which patient populations.

Keywords: Bone health; Bone metastases; Bone-targeted agents; Cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of bisphosphonate in high versus low bone turnover populations.
See this image and copyright information in PMC

References

    1. Fralick M., Bouganim N., Kremer R., Kekre N., Robertson S., Vandermeer L. Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results. J Bone Oncol. 2012;1(3):69–73. - PMC - PubMed
    1. Russell K., Amir E., Paterson A., Josse R., Addison C., Kuchuk I. Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol. 2013;2(4):167–173. - PMC - PubMed
    1. Addison C.L., Pond G.R., Zhao H., Mazzarello S., Vandermeer L., Goldstein R. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. SpringerPlus. 2014;3:577. - PMC - PubMed
    1. C.L. Addison, N. Bouganim, J. Hilton, L. Vandemeer, S. Dent, E. Amir, et al., A Phase II, multicenter trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events, Breast Cancer Res Treat. 2014;144(3):615-24. 10.1007/s10549-014-2906-x. Epub 2014 Mar 18. - DOI - PMC - PubMed
    1. Hutton B., Addison C., Campbell K., Fergusson D., Mazarello S., Clemons M. A systematic review of dosing frequency with bone targeted agents for patients with bone metastases from breast cancer. J Bone Oncol. 2013;2:123–131. - PMC - PubMed